Expansion of Senior Leadership Team enhances Voyager’s ability to articulate and execute on its vision to enable and advance transformational treatments for CNS diseases CAMBRIDGE, Mass. , Sept. 07, 2022 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience

Reader Interactions

Leave A Reply